SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " guardant " 18 found 🔀 AI-powered Shuffle
Guardant Health to Highlight Advances in Liquid Biopsy for Cancer Monitoring at ESMO 2026
Guardant Health and partners will present 25 abstracts on liquid biopsy advances for cancer monitoring at ESMO 2026.
Guardant Health (GH) Stock Looks Below Fair Value On A Huge Run
Guardant Health has turned into a dramatic long term story for shareholders, yet the real question now is whether the current US$158.60 price can be supported by the cash flows its business is expected to produce. With the stock sharply higher over several years and new clinical and regulatory developments landing, the focus has shifted to what the Discounted Cash Flow (DCF) view of its intrinsic value suggests about that price. Over the past 3 years the share price has risen by very large...
Guardant Health (GH) After Shield And Reveal Data Is The Undervalued Story Still Intact
Guardant Health (GH) is back in focus after new data on its Shield blood test for colorectal cancer screening and Guardant Reveal test for melanoma residual disease were released in October 2026. Investors have taken notice of this Shield and Guardant Reveal data, even as the Guardant Health share price has eased in the short term. The 1-month share price return is down 9.32% and the 7-day share price return is down 5.30%. At the same time, the 1-year total shareholder return of 142.29% and...
Is 99% Screening Adherence Altering The Investment Case For Guardant Health (GH)?
Guardant Health reported new data from its Shield blood-based colorectal cancer screening test, including modeling and rural clinic results, indicating very high real world adherence and meaningful impact on screening pathways for average risk adults. The 99% completion rate for Shield in two rural South Carolina clinics highlights how a simple blood draw can address screening gaps in medically underserved communities and reshape demand across Guardant Health's screening franchise. This...
Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026
PALO ALTO, Calif., October 08, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2026 after market close on Thursday, November 5, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
American Cancer Society adds Guardant Health's Shield blood test to colorectal cancer screening guideline
'By making colorectal cancer screening more accessible with a blood-based option in conjunction with other established methodologies, we can get people screened.'
Guardant Health (GH) Stock Could Be Undervalued Despite Its 5x Run
Guardant Health has turned into one of the stronger movers in U.S. healthcare, with the share price now reflecting very optimistic expectations in the eyes of many investors. With that backdrop, the central question is whether the current valuation is properly supported by the cash flows the business can generate over time. The stock has delivered a very large 3 year return of about 5x, which puts real pressure on the cash flow story to support such a move. Recent coverage gains for Guardant...
Guardant Health co-CEO Helmy Eltoukhy on breast cancer test
Guardant Health co-CEO Helmy Eltoukhy joins CNBC's 'Squawk on the Street' to discuss the breast cancer test, managing cancer with a blood test, and more.
Guardant Health (GH) Will Present 20 Abstracts At WCLC 2026
Guardant Health (NasdaqGS:GH) plans to present 20 abstracts at the World Conference on Lung Cancer 2026. The research covers liquid biopsy, methylation based detection methods, AI driven analysis and real world clinical data in lung cancer. Several abstracts focus on machine learning models aimed at assessing metastasis risk and refining diagnostic workflows for clinicians. Guardant Health's WCLC 2026 abstract slate signals broader research momentum that our work places in a wider context...
Guardant Health (GH) Lands First FDA Cleared Breast Cancer Liquid Biopsy Role
Guardant Health (NasdaqGS:GH) received FDA approval for its Guardant360 CDx liquid biopsy as a companion diagnostic in advanced HR-positive, HER2-negative breast cancer. The decision makes Guardant360 CDx the first FDA approved liquid biopsy companion diagnostic for longitudinal ctDNA testing in breast cancer care. The approval is supported by clinical trial data where early detection of ESR1 mutations using Guardant360 CDx informed treatment changes for patients. The Guardant360 CDx breast...
Testing & Diagnostics Services Stocks Q2 Results: Benchmarking Guardant Health (NASDAQ:GH)
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Guardant Health (NASDAQ:GH) and its peers.
What Makes Guardant Health (GH) a Compelling Bet?
Artisan Partners, an investment management company, released its second-quarter 2026 investor letter for the “Artisan Mid Cap Fund”. The letter can be downloaded here. Global equities rebounded sharply in Q2 2026, recovering from March lows as resilient economic data, strong corporate earnings, and continued AI investment improved investor sentiment despite inflation concerns, delayed rate cuts, and […]
Guardant Health Faces a $245 Million Patent Judgment, But Its Newer Tests Could Offer Protection
Guardant Health, Inc. (NASDAQ:GH) faces a costly legal setback after a US court ordered the cancer-testing company to pay more than $245.2 million in a DNA-sequencing patent dispute. The final judgment upheld a 2023 jury verdict finding that Guardant willfully infringed two DNA-sequencing patents asserted by TwinStrand Biosciences and the University of Washington. The financial […]
Is It Too Late To Consider Guardant Health (GH) After Its 100% One Year Surge?
If you are wondering whether Guardant Health at around US$90.36 is still fairly priced or starting to look stretched, the key question is what that tag says about the underlying business. The stock has seen sharp swings, with a 15.0% move over the last 7 days, 6.1% over 30 days, a 100.9% return over 1 year and a 268.7% return over 3 years, while the 5 year return sits at a 42.9% decline and the year to date return at an 11.2% decline. Recent headlines around Guardant Health have focused on...
Guardant Health (GH) Valuation Check After Strong 1 Year Return And Recent 90 Day Pullback
Guardant Health (GH) has drawn fresh attention as investors look at its recent share performance alongside its growing precision oncology business, including liquid biopsy tests and data services for cancer detection and treatment decisions. See our latest analysis for Guardant Health. At a latest share price of US$93.83, Guardant Health has seen a sharp 10.9% 7 day share price return and a 1 year total shareholder return above 100%. However, the 90 day share price return of a 7.77% decline...
Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America
Shield Across America mobile screening tour launches during Colorectal Cancer Awareness Month to address nation’s dangerously low screening rates by bringing Shield blood test directly to Americans Route will focus on rural communities across the country with the lowest screening rates and highest CRC incidence and mortality Shield is proven to increase screening rates with a 93% adherence Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of Shield Across America, a historic coast-to-coast mobile screening tour bringing Shield, the first and only FDA-approved blood test as a primary colorectal cancer (CRC) screening option and recommended in national guidelines , directly to over 100 communities across the country from Las Vegas to Hartford, Atlanta and more. Mobile screening bus providing Shield by Guardant Health, the first and only FDA-approved blood test for primary colorectal cancer screening From national sporting events to
Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield Blood Test, Sharing His Experience Getting Screened
1 in 3 eligible Americans avoid colorectal cancer (CRC) screenings because traditional methods are viewed as unpleasant and inconvenient Guardant's FDA-approved Shield blood test offers an easier, more convenient way to screen with a blood draw from any prescribing healthcare provider for adults 45+ at average risk for CRC Motivated by his mother’s cancer fight, Dempsey is calling on Americans to prioritize getting screened this CRC Awareness Month Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its partnership with actor and cancer advocate Patrick Dempsey to increase awareness about colorectal cancer (CRC) screening and the Shield® blood test. Approved by the U.S. Food and Drug Administration (FDA) in 2024 and recommended in national guidelines , Shield offers an easier way to screen for colorectal cancer (CRC) with just a blood draw for eligible individuals 45 and over at average risk for the disease. Patrick Dempsey, actor and cancer
Guardant Health and Trial Library to expand access to US cancer trials
Trial Library’s platform is said to provide access to trials within community-based settings, spanning over 320 clinics.